STOCK TITAN
  1. Home
  2. News
  3. CRBP

Corbus Pharmaceuticals Holdings Inc - CRBP STOCK NEWS

Welcome to our dedicated news page for Corbus Pharmaceuticals Holdings (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corbus Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corbus Pharmaceuticals Holdings's position in the market.

News
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Rhea-AI Summary
Corbus Pharmaceuticals announced that an abstract providing updated data from a Phase 1 clinical study with CRB-701 has been accepted for presentation at the 2024 ASCO Annual Meeting. CRB-701 is a next-generation antibody-drug-conjugate targeting Nectin-4, showing promising safety and efficacy data in urothelial cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the initiation of a Phase 1 clinical trial for CRB-701, an ADC targeting Nectin-4 in patients with advanced solid tumors. The trial aims to evaluate safety, efficacy, and PK in participants with high Nectin-4 expression, with promising data indicating differentiation from PADCEV. This milestone signifies potential clinical benefits for patients with mUC and other Nectin-4 positive tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial
-
News
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. provides a corporate update and financial results for 2023, highlighting progress in advancing their pipeline. Encouraging data for CRB-701, CRB-601, and CRB-913 was presented, with significant capital raised in 2024 and the appointment of Dr. Dominic Smethurst as Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.46%
Tags
earnings
News
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO, Yuval Cohen, to participate in panel discussion at BMO Capital Markets Inaugural Obesity Summit on March 20, 2024 in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
-
News
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. appoints Dr. Dominic Smethurst as Chief Medical Officer to lead the clinical development of their investigational oncology drugs CRB-701 and CRB-601, developed in partnership with CSPC, and CRB-913. Dr. Smethurst's expertise in developing novel oncology therapeutics will enhance Corbus' precision oncology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.4%
Tags
management
-
News
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. CEO to provide corporate update at Oppenheimer 34th Annual Healthcare Life Sciences Conference. The CEO will participate in one-on-one investor meetings and give a presentation on February 14, 2024, at 8:40 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
conferences
News
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has closed a public offering of 4,973,750 shares of its common stock, generating approximately $94.5 million before underwriting discounts and expenses. The offering price was $19.00 per share, with Jefferies as the sole book-running manager. The company also announced the exercise in full of the underwriters' option to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Corbus Pharmaceuticals Announces Pricing of Public Offering
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, totaling approximately $82.2 million. The underwriters have also been granted a 30-day option to purchase up to an additional 648,750 shares of its common stock. All securities in the offering are being sold by Corbus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
offering
-
News
Corbus Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. plans to offer and sell shares of its common stock in an underwritten registered public offering to fund the clinical development of its pipeline and for working capital and other general corporate purposes. Jefferies is acting as sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
offering
News
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Rhea-AI Summary
Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium. The study demonstrates a 43% objective response rate and 71% disease control rate at predicted therapeutically relevant doses. The drug was well-tolerated with no dose limiting toxicities observed. The study is ongoing in China and has shown promising clinical activity in multiple nectin-4 expressing tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
249.41%
Tags
none
Stock CRBP logo
Corbus Pharmaceuticals Holdings Inc

Nasdaq:CRBP

CRBP Rankings

#3266 Ranked by Market Cap
#601 Ranked by Stock Gains
N/A Ranked by Dividends

CRBP Stock Data

429.22M
6.77M
0.69%
56.95%
4.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Norwood

About CRBP

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.